Tags

Type your tag names separated by a space and hit enter

Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13.
Euro Surveill. 2014 Feb 13; 19(6)ES

Abstract

In the fifth season of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE), we undertook a multicentre case-control study (MCCS) in seven European Union (EU) Member States to measure 2012/13 influenza vaccine effectiveness against medically attended influenza-like illness (ILI) laboratory confirmed as influenza. The season was characterised by substantial co-circulation of influenza B, A(H1N1)pdm09 and A(H3N2) viruses. Practitioners systematically selected ILI patients to swab ≤7 days of symptom onset. We compared influenza-positive by type/subtype to influenza-negative patients among those who met the EU ILI case definition. We conducted a complete case analysis using logistic regression with study as fixed effect and calculated adjusted vaccine effectiveness (AVE), controlling for potential confounders (age, sex, symptom onset week and presence of chronic conditions). We calculated AVE by type/subtype. Study sites sent 7,954 ILI/acute respiratory infection records for analysis. After applying exclusion criteria, we included 4,627 ILI patients in the analysis of VE against influenza B (1,937 cases), 3,516 for A(H1N1)pdm09 (1,068 cases) and 3,340 for influenza A(H3N2) (730 cases). AVE was 49.3% (95% confidence interval (CI): 32.4 to 62.0) against influenza B, 50.4% (95% CI: 28.4 to 65.6) against A(H1N1)pdm09 and 42.2% (95% CI: 14.9 to 60.7) against A(H3N2). Our results suggest an overall low to moderate AVE against influenza B, A(H1N1)pdm09 and A(H3N2), between 42 and 50%. In this season with many co-circulating viruses, the high sample size enabled stratified AVE by type/subtype. The low estimates indicate seasonal influenza vaccines should be improved to achieve acceptable protection levels.

Authors+Show Affiliations

EpiConcept, Paris, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

24556348

Citation

Kissling, E, et al. "Influenza Vaccine Effectiveness Estimates in Europe in a Season With Three Influenza Type/subtypes Circulating: the I-MOVE Multicentre Case-control Study, Influenza Season 2012/13." Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, vol. 19, no. 6, 2014.
Kissling E, Valenciano M, Buchholz U, et al. Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13. Euro Surveill. 2014;19(6).
Kissling, E., Valenciano, M., Buchholz, U., Larrauri, A., Cohen, J. M., Nunes, B., Rogalska, J., Pitigoi, D., Paradowska-Stankiewicz, I., Reuss, A., Jiménez-Jorge, S., Daviaud, I., Guiomar, R., O'Donnell, J., Necula, G., Głuchowska, M., & Moren, A. (2014). Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13. Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, 19(6).
Kissling E, et al. Influenza Vaccine Effectiveness Estimates in Europe in a Season With Three Influenza Type/subtypes Circulating: the I-MOVE Multicentre Case-control Study, Influenza Season 2012/13. Euro Surveill. 2014 Feb 13;19(6) PubMed PMID: 24556348.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13. AU - Kissling,E, AU - Valenciano,M, AU - Buchholz,U, AU - Larrauri,A, AU - Cohen,J M, AU - Nunes,B, AU - Rogalska,J, AU - Pitigoi,D, AU - Paradowska-Stankiewicz,I, AU - Reuss,A, AU - Jiménez-Jorge,S, AU - Daviaud,I, AU - Guiomar,R, AU - O'Donnell,J, AU - Necula,G, AU - Głuchowska,M, AU - Moren,A, Y1 - 2014/02/13/ PY - 2014/2/22/entrez PY - 2014/2/22/pubmed PY - 2014/4/8/medline JF - Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin JO - Euro Surveill. VL - 19 IS - 6 N2 - In the fifth season of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE), we undertook a multicentre case-control study (MCCS) in seven European Union (EU) Member States to measure 2012/13 influenza vaccine effectiveness against medically attended influenza-like illness (ILI) laboratory confirmed as influenza. The season was characterised by substantial co-circulation of influenza B, A(H1N1)pdm09 and A(H3N2) viruses. Practitioners systematically selected ILI patients to swab ≤7 days of symptom onset. We compared influenza-positive by type/subtype to influenza-negative patients among those who met the EU ILI case definition. We conducted a complete case analysis using logistic regression with study as fixed effect and calculated adjusted vaccine effectiveness (AVE), controlling for potential confounders (age, sex, symptom onset week and presence of chronic conditions). We calculated AVE by type/subtype. Study sites sent 7,954 ILI/acute respiratory infection records for analysis. After applying exclusion criteria, we included 4,627 ILI patients in the analysis of VE against influenza B (1,937 cases), 3,516 for A(H1N1)pdm09 (1,068 cases) and 3,340 for influenza A(H3N2) (730 cases). AVE was 49.3% (95% confidence interval (CI): 32.4 to 62.0) against influenza B, 50.4% (95% CI: 28.4 to 65.6) against A(H1N1)pdm09 and 42.2% (95% CI: 14.9 to 60.7) against A(H3N2). Our results suggest an overall low to moderate AVE against influenza B, A(H1N1)pdm09 and A(H3N2), between 42 and 50%. In this season with many co-circulating viruses, the high sample size enabled stratified AVE by type/subtype. The low estimates indicate seasonal influenza vaccines should be improved to achieve acceptable protection levels. SN - 1560-7917 UR - https://www.unboundmedicine.com/medline/citation/24556348/Influenza_vaccine_effectiveness_estimates_in_Europe_in_a_season_with_three_influenza_type/subtypes_circulating:_the_I_MOVE_multicentre_case_control_study_influenza_season_2012/13_ L2 - http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20701 DB - PRIME DP - Unbound Medicine ER -